Baidu
map
HEPATOL RES 润色咨询

HEPATOLOGY RESEARCH

出版年份：1997 年文章数：1255 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：9.3% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向： 肝癌 <br>经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0<br>经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。<br>审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0<br>经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2024-04-23 国统乃我辈之愿 来自海南省

    为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向： 肝癌 <br>经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0<br>经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。<br>审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0<br>经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2024-02-10 邓医生的株式会社 来自安徽省

    审稿速度:1.0
    经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向： 肝癌 <br>经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0<br>经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。<br>审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0<br>经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2021-08-09 148bf9cam55暂无昵称

    偏重的研究方向： 肝癌
    经验分享：这个杂志送外审了状态也还是Under Review吗

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向： 肝癌 <br>经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0<br>经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。<br>审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0<br>经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2022-06-07 ms7000000962482370

    审稿速度:2.0
    经验分享：不是审稿周期蛮短的吗，怎么一直没消息

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向： 肝癌 <br>经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0<br>经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。<br>审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0<br>经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2023-08-24 ms2000000070952725 来自河南省

    投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向： 肝癌 <br>经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0<br>经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。<br>审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0<br>经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2023-07-13 xujianbo1987 来自江苏省

    请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向： 肝癌 <br>经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0<br>经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。<br>审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0<br>经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2022-07-10 YJJJJJ

    中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。
    审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。

    10

    展开10条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向： 肝癌 <br>经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0<br>经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。<br>审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0<br>经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2022-08-13 Ysbstsvshndudnd

    想咨询一下这个杂志是OA的吗？版面费大概多少？

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向： 肝癌 <br>经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0<br>经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。<br>审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0<br>经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2022-05-06 ms1000000867109818

    请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！

    3

    展开3条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2199985, encodeId=ad8a219998513, content=为啥总是提醒我手稿无法在投稿系统上形成pdf文件？手稿不是只读格式呀，哪里出问题？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Apr 23 17:39:51 CST 2024, time=2024-04-23, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2186828, encodeId=81eb2186828d4, content=审稿速度:1.0<br>经验分享：投稿后也是Under review了一个多月，最后没有给意见直接拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓医生的株式会社, createdTime=Sat Feb 10 20:50:43 CST 2024, time=2024-02-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1006515, encodeId=31ee100651598, content=偏重的研究方向： 肝癌 <br>经验分享：这个杂志送外审了状态也还是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Aug 09 23:42:05 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224919, encodeId=927812249194b, content=审稿速度:2.0<br>经验分享：不是审稿周期蛮短的吗，怎么一直没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=269f5411736, createdName=ms7000000962482370, createdTime=Tue Jun 07 10:07:59 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154389, encodeId=24e92154389ff, content=投liver international被拒后转投hepatology research。5月31号投稿，6月27大修，7月5号修回，8月7号小修，8月14号修回，8月24号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48fa5604048, createdName=ms2000000070952725, createdTime=Thu Aug 24 16:42:44 CST 2023, time=2023-08-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2147899, encodeId=2b05214e899c7, content=请教各位，我投稿时候，编辑部总是让我提供Disclosure of Ethical Statements。请问这个怎么提交啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03b572282, createdName=xujianbo1987, createdTime=Thu Jul 13 21:01:13 CST 2023, time=2023-07-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1231667, encodeId=fcb9123166e23, content=中了第二篇，肝癌临床多中心回顾性研究。一审3周，二审3周。相对来说还是很快。<br>审稿人评论比较专业，为此回复审稿人的点对点回答的参考文献甚至超过了50篇。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sun Jul 10 19:03:55 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238484, encodeId=9dec1238484ab, content=想咨询一下这个杂志是OA的吗？版面费大概多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66495497077, createdName=Ysbstsvshndudnd, createdTime=Sat Aug 13 16:29:32 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217270, encodeId=bf22121e2707f, content=请问这个期刊的论文的格式中附录应该写什么内容？正文里要求不在段落行尾使用Enter应该怎么换行？文中的图片要一个文件一个文件的上传吗？有没有了解的大神，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri May 06 08:45:29 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214941, encodeId=ca561214941be, content=审稿速度:1.0<br>经验分享：审稿非常快，从投稿到接收用时一个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Wed Apr 27 07:46:57 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2022-04-27 YJJJJJ

    审稿速度:1.0
    经验分享：审稿非常快，从投稿到接收用时一个月。

    2

    展开2条回复
共93条页码: 1/10页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map